One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy

Mio Hosokawa, Yuki Morizane, Masayuki Hirano, Shuhei Kimura, Fumiaki Kumase, Yusuke Shiode, Shinichiro Doi, Shinji Toshima, Mika Hosogi, Atsushi Fujiwara, Toshiharu Mitsuhashi, Fumio Shiraga

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: To evaluate the 1-year treatment outcomes of intravitreal aflibercept injections (IVA) using a treat-and-extend regimen for polypoidal choroidal vasculopathy (PCV). Methods: Thirty-seven eyes with treatment-naive PCV treated with IVA using a treat-and-extend regimen for 1 year were reviewed retrospectively. The main outcome measures were changes in the best-corrected visual acuity (BCVA) and central retinal thickness (CRT), and the treatment interval at 1 year. The predictive factors for patients who could not continue to extend the treatment interval because of poor response to IVA or recurrence were analyzed. Results: The mean logarithm of the minimum angle of resolution BCVA improved from 0.37 at baseline to 0.21 at 1 year (P < 0.001). The mean CRT decreased from 342.3 μm at baseline to 196.6 μm at 1 year (P < 0.001). The mean treatment interval was 9.7 weeks at 1 year (4 weeks in 11 eyes [29.7%], 6 weeks in 1 eye [2.7%], 8 weeks in 2 eyes [5.4%], 10 weeks in 1 eye [2.7%], and 12 weeks in 22 eyes [59.5%]). A larger number of polypoidal lesions at baseline was predictive for patients who could not continue to extend the treatment interval. Conclusions: IVA using a treat-and-extend regimen is effective for improving BCVA and CRT in eyes with PCV.

Original languageEnglish
Pages (from-to)150-158
Number of pages9
JournalJapanese Journal of Ophthalmology
Volume61
Issue number2
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Intravitreal Injections
Visual Acuity
Therapeutics
aflibercept
Outcome Assessment (Health Care)
Recurrence

Keywords

  • Aflibercept
  • Polypoidal choroidal vasculopathy
  • Treat-and-extend regimen

ASJC Scopus subject areas

  • Ophthalmology

Cite this

One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy. / Hosokawa, Mio; Morizane, Yuki; Hirano, Masayuki; Kimura, Shuhei; Kumase, Fumiaki; Shiode, Yusuke; Doi, Shinichiro; Toshima, Shinji; Hosogi, Mika; Fujiwara, Atsushi; Mitsuhashi, Toshiharu; Shiraga, Fumio.

In: Japanese Journal of Ophthalmology, Vol. 61, No. 2, 01.03.2017, p. 150-158.

Research output: Contribution to journalArticle

@article{ef9ff309d01e4835bf5a0ca48ea0fc86,
title = "One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy",
abstract = "Purpose: To evaluate the 1-year treatment outcomes of intravitreal aflibercept injections (IVA) using a treat-and-extend regimen for polypoidal choroidal vasculopathy (PCV). Methods: Thirty-seven eyes with treatment-naive PCV treated with IVA using a treat-and-extend regimen for 1 year were reviewed retrospectively. The main outcome measures were changes in the best-corrected visual acuity (BCVA) and central retinal thickness (CRT), and the treatment interval at 1 year. The predictive factors for patients who could not continue to extend the treatment interval because of poor response to IVA or recurrence were analyzed. Results: The mean logarithm of the minimum angle of resolution BCVA improved from 0.37 at baseline to 0.21 at 1 year (P < 0.001). The mean CRT decreased from 342.3 μm at baseline to 196.6 μm at 1 year (P < 0.001). The mean treatment interval was 9.7 weeks at 1 year (4 weeks in 11 eyes [29.7{\%}], 6 weeks in 1 eye [2.7{\%}], 8 weeks in 2 eyes [5.4{\%}], 10 weeks in 1 eye [2.7{\%}], and 12 weeks in 22 eyes [59.5{\%}]). A larger number of polypoidal lesions at baseline was predictive for patients who could not continue to extend the treatment interval. Conclusions: IVA using a treat-and-extend regimen is effective for improving BCVA and CRT in eyes with PCV.",
keywords = "Aflibercept, Polypoidal choroidal vasculopathy, Treat-and-extend regimen",
author = "Mio Hosokawa and Yuki Morizane and Masayuki Hirano and Shuhei Kimura and Fumiaki Kumase and Yusuke Shiode and Shinichiro Doi and Shinji Toshima and Mika Hosogi and Atsushi Fujiwara and Toshiharu Mitsuhashi and Fumio Shiraga",
year = "2017",
month = "3",
day = "1",
doi = "10.1007/s10384-016-0492-7",
language = "English",
volume = "61",
pages = "150--158",
journal = "Japanese Journal of Ophthalmology",
issn = "0021-5155",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy

AU - Hosokawa, Mio

AU - Morizane, Yuki

AU - Hirano, Masayuki

AU - Kimura, Shuhei

AU - Kumase, Fumiaki

AU - Shiode, Yusuke

AU - Doi, Shinichiro

AU - Toshima, Shinji

AU - Hosogi, Mika

AU - Fujiwara, Atsushi

AU - Mitsuhashi, Toshiharu

AU - Shiraga, Fumio

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Purpose: To evaluate the 1-year treatment outcomes of intravitreal aflibercept injections (IVA) using a treat-and-extend regimen for polypoidal choroidal vasculopathy (PCV). Methods: Thirty-seven eyes with treatment-naive PCV treated with IVA using a treat-and-extend regimen for 1 year were reviewed retrospectively. The main outcome measures were changes in the best-corrected visual acuity (BCVA) and central retinal thickness (CRT), and the treatment interval at 1 year. The predictive factors for patients who could not continue to extend the treatment interval because of poor response to IVA or recurrence were analyzed. Results: The mean logarithm of the minimum angle of resolution BCVA improved from 0.37 at baseline to 0.21 at 1 year (P < 0.001). The mean CRT decreased from 342.3 μm at baseline to 196.6 μm at 1 year (P < 0.001). The mean treatment interval was 9.7 weeks at 1 year (4 weeks in 11 eyes [29.7%], 6 weeks in 1 eye [2.7%], 8 weeks in 2 eyes [5.4%], 10 weeks in 1 eye [2.7%], and 12 weeks in 22 eyes [59.5%]). A larger number of polypoidal lesions at baseline was predictive for patients who could not continue to extend the treatment interval. Conclusions: IVA using a treat-and-extend regimen is effective for improving BCVA and CRT in eyes with PCV.

AB - Purpose: To evaluate the 1-year treatment outcomes of intravitreal aflibercept injections (IVA) using a treat-and-extend regimen for polypoidal choroidal vasculopathy (PCV). Methods: Thirty-seven eyes with treatment-naive PCV treated with IVA using a treat-and-extend regimen for 1 year were reviewed retrospectively. The main outcome measures were changes in the best-corrected visual acuity (BCVA) and central retinal thickness (CRT), and the treatment interval at 1 year. The predictive factors for patients who could not continue to extend the treatment interval because of poor response to IVA or recurrence were analyzed. Results: The mean logarithm of the minimum angle of resolution BCVA improved from 0.37 at baseline to 0.21 at 1 year (P < 0.001). The mean CRT decreased from 342.3 μm at baseline to 196.6 μm at 1 year (P < 0.001). The mean treatment interval was 9.7 weeks at 1 year (4 weeks in 11 eyes [29.7%], 6 weeks in 1 eye [2.7%], 8 weeks in 2 eyes [5.4%], 10 weeks in 1 eye [2.7%], and 12 weeks in 22 eyes [59.5%]). A larger number of polypoidal lesions at baseline was predictive for patients who could not continue to extend the treatment interval. Conclusions: IVA using a treat-and-extend regimen is effective for improving BCVA and CRT in eyes with PCV.

KW - Aflibercept

KW - Polypoidal choroidal vasculopathy

KW - Treat-and-extend regimen

UR - http://www.scopus.com/inward/record.url?scp=85001833264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85001833264&partnerID=8YFLogxK

U2 - 10.1007/s10384-016-0492-7

DO - 10.1007/s10384-016-0492-7

M3 - Article

VL - 61

SP - 150

EP - 158

JO - Japanese Journal of Ophthalmology

JF - Japanese Journal of Ophthalmology

SN - 0021-5155

IS - 2

ER -